Literature DB >> 1559341

Growth factors and corneal endothelial cells: I. Stimulation of bovine corneal endothelial cell DNA synthesis by defined growth factors.

P G Woost1, M M Jumblatt, R A Eiferman, G S Schultz.   

Abstract

Peptide growth factors and other physiological growth modifiers were evaluated for their ability to stimulate DNA synthesis in early passage cultures of bovine corneal endothelial cells (BCEC). Increasing concentrations of newborn bovine serum (0.5-10%) causes a progressive increase in DNA synthesis, which approached a plateau at 10% serum. Supplementing medium with 10% serum from different lots of newborn bovine serum or fetal bovine serum stimulated significantly different levels of DNA synthesis by BCEC. Addition of epidermal growth factor (EGF) (2 nM) to medium containing 10% newborn or fetal bovine serum further increased DNA synthesis. Dose-response curves for EGF, transforming growth factor-alpha, basic fibroblast growth factor (bFGF), and insulin-like growth factor I showed that each significantly stimulated high levels of DNA synthesis (200-700% increase) compared with BCEC cultured in serum-free medium. Vaccinia growth factor, insulin, and transforming growth factor-beta each significantly stimulated lower levels of DNA synthesis (30-200% increase), whereas nerve growth factor, multiplication stimulating activity, and platelet-derived growth factor all failed to significantly stimulate DNA synthesis above the level of serum-free medium. Other physiological growth modifiers were tested for their effects on DNA synthesis of BCEC. Transferrin and low levels of 3',5'-cyclic monophosphate (cAMP) stimulated very low levels of DNA synthesis (50% increase) whereas linoleic acid, high levels of selenium, or cAMP each inhibited DNA synthesis 25-75% below the level of BCEC cultured in serum-free medium. A series of eight formulations containing various combinations of EGF, FGF, insulin, transferrin, selenium, linoleic acid, retinoic acid, cAMP, heparin, and endothelial cell growth factor were tested for their mitogenic action on BCEC cultures. A formulation containing EGF, insulin, transferrin, selenium, and linoleic acid (EGF + ITSL) stimulated the highest level of DNA synthesis of BCEC, which was approximately 25% higher than the increase stimulated by addition of 10% newborn bovine serum. The formulation consisting of EGF + ITSL was also evaluated as a supplement to corneal storage media. Addition of EGF + ITSL to three corneal storage media (McCarey-Kaufman, K-Sol, CSM) significantly stimulated increases in cell numbers of approximately 50% above the unsupplemented corneal storage media. These results demonstrate that BCEC respond selectively to different defined peptide growth factors and physiological growth modifiers, and suggest that supplementation of corneal storage media with a defined formulation (EGF + ITSL) may enhance corneal endothelial cell density.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1559341     DOI: 10.1097/00003226-199201000-00001

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  13 in total

1.  Effect of serum and insulin modulation on the organization and morphology of matrix synthesized by bovine corneal stromal cells.

Authors:  Ericka M Bueno; Nima Saeidi; Suzanna Melotti; Jeffrey W Ruberti
Journal:  Tissue Eng Part A       Date:  2009-11       Impact factor: 3.845

2.  A role for Notch signaling in corneal wound healing.

Authors:  Aihua Ma; Bojun Zhao; Mike Boulton; Julie Albon
Journal:  Wound Repair Regen       Date:  2010-12-06       Impact factor: 3.617

3.  Factors affecting bovine corneal endothelial cell density in vitro.

Authors:  E W Johnstone; H C Wong; D J Coster; K A Williams
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

4.  Triple combination of siRNAs targeting TGFβ1, TGFβR2, and CTGF enhances reduction of collagen I and smooth muscle actin in corneal fibroblasts.

Authors:  Sriniwas Sriram; Paulette Robinson; Liya Pi; Alfred S Lewin; Gregory Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-17       Impact factor: 4.799

5.  MicroRNA signature in wound healing following excimer laser ablation: role of miR-133b on TGFβ1, CTGF, SMA, and COL1A1 expression levels in rabbit corneal fibroblasts.

Authors:  Paulette M Robinson; Tsai-Der Chuang; Sriniwas Sriram; Liya Pi; Xiao Ping Luo; Bryon E Petersen; Gregory S Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-23       Impact factor: 4.799

6.  Colon cancer cells that are not growth inhibited by TGF-beta lack functional type I and type II TGF-beta receptors.

Authors:  S L MacKay; L R Yaswen; R W Tarnuzzer; L L Moldawer; K I Bland; E M Copeland; G S Schultz
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

7.  Effect of connective tissue growth factor on protein kinase expression and activity in human corneal fibroblasts.

Authors:  Siva S Radhakrishnan; Timothy D Blalock; Paulette M Robinson; Genevieve Secker; Julie Daniels; Gary R Grotendorst; Gregory S Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-13       Impact factor: 4.799

8.  Proteolytic processing of connective tissue growth factor in normal ocular tissues and during corneal wound healing.

Authors:  Paulette M Robinson; Tyler S Smith; Dilan Patel; Meera Dave; Alfred S Lewin; Liya Pi; Edward W Scott; Sonal S Tuli; Gregory S Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-13       Impact factor: 4.799

9.  Optimization of culture conditions for porcine corneal endothelial cells.

Authors:  Stéphanie Proulx; Jean-Michel Bourget; Nicolas Gagnon; Sophie Martel; Alexandre Deschambeault; Patrick Carrier; Claude J Giasson; François A Auger; Isabelle Brunette; Lucie Germain
Journal:  Mol Vis       Date:  2007-04-03       Impact factor: 2.367

10.  Sex-Specific Response to Combinations of Shear Stress and Substrate Stiffness by Endothelial Cells In Vitro.

Authors:  Bryan D James; Josephine B Allen
Journal:  Adv Healthc Mater       Date:  2021-06-17       Impact factor: 11.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.